<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate
On-demand webinar:

Bridging the distance to large-scale GMP manufacturing of viral vectors


Access the webinar

Webinar overview: 

Gene therapy has come a long way in the last decade, with multiple recent approvals. The industry hasn’t remained static; neither has the technology. 

In this webinar, our Vector Process Development Director, Margherita Neri, Ph.D., discusses how AGC Biologics' platform process can help developers move from the sequence of the gene of interest to the GMP manufacturing of the first vector batch in less than one year, using the latest bioreactor technology alongside our proprietary viral vector processes.

Watch and learn about: 

  • AGC Biologics’ strong regulatory track record, capabilities and experience with developing vectors that scale. 
  • The methodologies for generating reliable processes for AAV and LVV production. 
  • The power of using the latest technology, Cytiva's iCELLis bioreactor systems, to enhance virus productivity. 
  • AGC Biologics' BravoAAV™ and ProntoLVV™ platform processes.

Additional Cell & Gene Therapy

Educational Content

Like a Tailored Suit download graphic no iconBuilding Customized Viral Vector Programs

Access white paper

Outsourcing Allogeneic Cell Therapy - download graphic no iconAccelerating Allogeneic Cell Therapies 

Access white paper

large-scale aav manufacturing download graphic no iconCreating a Large-Scale AAV Platform

Access white paper